# A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body

> **NCT01045317** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 10 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)

## Interventions

- **DRUG:** PF-04776548

## Key facts

- **NCT ID:** NCT01045317
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2010-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01045317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01045317, "A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01045317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*